News

The Manila Times
manilatimes.net > 02/20/2026 > tmt-newswire > globenewswire > fda-accepts-new-drug-application-for-roches-giredestrant-in-esr1-mutated-er-positive-advanced-breast-cancer > 2281731

FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer

5+ hour, 16+ min ago  (776+ words) Data from evERA are being used to support filing submissions to other global health authorities. Our extensive giredestrant clinical development programme spans multiple treatment settings and lines of therapy, reflecting our commitment to deliver innovative medicines to as many people…...

The Manila Times
manilatimes.net > 02/14/2026 > tmt-newswire > plentisoft > golden-group-international-celebrates-serving-commercial-government-and-institutional-facilities-with-top-menstrual-care-product-dispensers-and-receptacles-for-over-18-years > 2278465

Golden Group International Celebrates Serving Commercial, Government, and Institutional Facilities with Top Menstrual Care Product Dispensers and Receptacles for Over 18 Years

5+ day, 19+ hour ago  (372+ words) Patterson, NY, February 4, 2026 /MarketersMEDIA/ -- Committed to offering clients a wide range of efficient and effective products, over the last 18 years, Golden Group International (GGI) has earned an impressive reputation for its high-quality, reliable menstrual care product dispensers and receptacles that…...

The Manila Times
manilatimes.net > 02/13/2026 > tmt-newswire > pr-newswire > stop-guessing-your-skincare-in-korea-nol-world-launches-a-personalized-k-beauty-tour-in-seoul > 2278160

Stop Guessing Your Skincare in Korea: NOL World Launches a Personalized K-Beauty Tour in Seoul

6+ day, 20+ hour ago  (294+ words) **media[937602]**Offers tailored 1-on-1 skin analysis and expert-guided drugstore'curation with up to 38% launch discountExpanding lifestyle-driven travel content that helps visitors experience Korea in a more personal waySEOUL'South Korea, Feb. 13, 2026 /PRNewswire/ --'NOL World, the premier South Korean travel and ticketing platform…...

The Manila Times
manilatimes.net > 01/12/2026 > tmt-newswire > globenewswire > press-release-biocartis-nv-biocartis-to-collaborate-with-mayo-clinic-on-breast-cancer-gene-signatures > 2257381

Press Release Biocartis NV: Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures

1+ mon, 1+ week ago  (134+ words) PRESS RELEASE, 01/12/2026, 10:00 EST Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures "Optimal care depends on timely access to test results. Rapid local diagnostics can shorten the time to determine patients" appropriate therapeutic pathway. Our goal is to…...

The Manila Times
manilatimes.net > 01/08/2026 > tmt-newswire > globenewswire > inspira-outlines-strategic-vision-and-transaction-framework-for-breast-cancer-liquid-biopsy-expansion > 2255499

Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

1+ mon, 1+ week ago  (750+ words) Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion'The Manila Times Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion Company details contemplated transaction structure designed to preserve shareholder value and enable…...

The Manila Times
manilatimes.net > 11/24/2025 > tmt-newswire > globenewswire > arvinas-announces-data-presentations-from-the-vepdegestrant-arv-471-clinical-development-program-at-the-2025-san-antonio-breast-cancer-symposium-sabcs > 2230278

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

2+ mon, 3+ week ago  (300+ words) The presentation details are as follows: Title: Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive/ human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC) Presenting Author: Erika P. Hamilton…...

The Manila Times
manilatimes.net > 11/19/2025 > tmt-newswire > pr-newswire > the-rise-of-advanced-maternal-age-ivf-basecare-medical-b2170hk-ai-undisturbed-culture-empowers-intelligent-assisted-reproduction > 2227344

The Rise of Advanced Maternal Age IVF: BaseCare Medical'-B(2170.HK) AI 'Undisturbed Culture' Empowers Intelligent Assisted Reproduction

3+ mon, 23+ hour ago  (187+ words) SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Data from the keynote report at the 18th Annual Conference of the Chinese Society of Reproductive Medicine (CSRM2025), held from November 12th to 15th, indicates that the average treatment age for women undergoing'IVF in China has risen to 33.6 years, highlighting…...

The Manila Times
manilatimes.net > 10/24/2025 > news > early-detection-of-breast-cancer-pushed > 2207674

Early detection of breast cancer pushed

3+ mon, 3+ week ago  (352+ words) MANILA, Philippines'The Philippine Health Insurance Corporation (PhilHealth) on Friday pushed for early detection of breast cancer with its Z benefit package expansion, in line with Breast Cancer Awareness Month. Under its YAKAP (Yaman ng Kalusugan Program), PhilHealth will cover selected…...

The Manila Times
manilatimes.net > 09/24/2025 > tmt-newswire > pr-newswire > the-menstrual-equity-project-launched-in-the-bahamas-to-boost-school-attendance-for-girls > 2189549

The 'Menstrual Equity Project' Launched in The Bahamas to Boost School Attendance for Girls

4+ mon, 3+ week ago  (256+ words) "There are girls stay home from school while menstruating, as they cannot afford to buy their napkins," said Mrs. Davis at the distribution event. "I couldn't believe the great need for this product here in the Bahamas in underserved communities....

The Manila Times
manilatimes.net > 09/22/2025 > tmt-newswire > globenewswire > positive-phase-iii-results-show-roches-giredestrant-significantly-improved-progression-free-survival-in-er-positive-advanced-breast-cancer > 2187991

Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

4+ mon, 4+ week ago  (845+ words) Our extensive giredestrant clinical development programme spans multiple treatment settings and lines of therapy, reflecting our commitment to deliver innovative medicines to as many people with ER-positive breast cancer as possible. Data from the evERA study will be submitted to…...